Literature DB >> 25786743

Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach.

Malcolm H Squires1, N Volkan Adsay, David M Schuster, Maria C Russell, Kenneth Cardona, Keith A Delman, Joshua H Winer, Deniz Altinel, Juan M Sarmiento, Bassel El-Rayes, Natalyn Hawk, Charles A Staley, Shishir K Maithel, David A Kooby.   

Abstract

BACKGROUND: Clinicians may order Octreoscan or positron emission tomography (PET) scan for staging patients with neuroendocrine tumors (NETs). (111)In-Octreoscan (Octreoscan) identifies tumors by radiolabeled targeting of somatostatin receptors, while 18F-fluorodeoxyglucose-positron emission tomography ((18)FDG-PET) measures differential tissue glucose transport. We assessed the sensitivity of both nuclear imaging modalities with pathologic correlation to define the best initial choice for NET staging after standard cross-sectional imaging.
METHODS: We identified all patients diagnosed with NETs of gastrointestinal or pancreatic origin who underwent nuclear imaging staging by Octreoscan and/or PET from 2000 to 2013. Imaging results were correlated with tumor differentiation and grade of pathology specimens.
RESULTS: Imaging and pathology results were identified for 153 patients. Of these, 131 underwent Octreoscan, 43 underwent PET, and 21 patients had both performed. Overall sensitivity of Octreoscan and PET for NET detection was similar (77 vs. 72 %; p = not significant). For well-differentiated NETs, Octreoscan (n = 124) demonstrated sensitivity of 80 vs. 60 % (p = 0.28) for PET (n = 30). For poorly-differentiated NETs, Octreoscan (n = 7) proved significantly less sensitive than PET (n = 13) (57 vs. 100 %; p = 0.02). The sensitivity of Octreoscan versus PET varied similarly when analyzed by WHO tumor grade: Grade 1 (79 vs. 52 %; p = 0.16), Grade 2 (85 vs. 86 %; p = not significant), and Grade 3 (57 vs. 100 %; p = 0.02).
CONCLUSIONS: Tumor differentiation can be used to guide selection of nuclear imaging modalities for staging gastrointestinal and pancreatic NETs. Octreoscan appears more sensitive than (18)FDG-PET for well-differentiated NETs, whereas (18)FDG-PET demonstrates superior sensitivity for poorly-differentiated NETs.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25786743     DOI: 10.1245/s10434-015-4471-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  24 in total

Review 1.  Principles of diagnosis and management of neuroendocrine tumours.

Authors:  Michael J Raphael; David L Chan; Calvin Law; Simron Singh
Journal:  CMAJ       Date:  2017-03-13       Impact factor: 8.262

2.  Pancreatic Neuroendocrine Tumor Secreting Vasoactive Intestinal Peptide and Dopamine With Pulmonary Emboli: A Case Report.

Authors:  Naris Nilubol; Esther M Freedman; Martha M Quezado; Dhaval Patel; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2016-09-01       Impact factor: 5.958

Review 3.  Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.

Authors:  Tetsuhide Ito; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2017-02       Impact factor: 3.243

Review 4.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 5.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

Review 6.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

7.  Performance of Multidetector Computed Tomography and Negative Versus Positive Enteric Contrast for Evaluation of Gastrointestinal Neuroendocrine Neoplasms.

Authors:  Ajaykumar C Morani; Shiva Gupta; Khaled M Elsayes; Ahmad I Mubarak; Ahmed M Khalaf; Priya R Bhosale; Jia Sun; Corey T Jensen; Vikas Kundra
Journal:  J Comput Assist Tomogr       Date:  2022-03-04       Impact factor: 2.081

Review 8.  Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

9.  AAVP displaying octreotide for ligand-directed therapeutic transgene delivery in neuroendocrine tumors of the pancreas.

Authors:  Tracey L Smith; Ziqiang Yuan; Marina Cardó-Vila; Carmen Sanchez Claros; Asha Adem; Min-Hui Cui; Craig A Branch; Juri G Gelovani; Steven K Libutti; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-16       Impact factor: 11.205

10.  Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.

Authors:  Clément Morgat; Fritz-Line Vélayoudom-Céphise; Paul Schwartz; Martine Guyot; Delphine Gaye; Delphine Vimont; Jürgen Schulz; Joachim Mazère; Marie-Laure Nunes; Denis Smith; Elif Hindié; Philippe Fernandez; Antoine Tabarin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-01-28       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.